Ardelyx (ARDX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
The annual meeting is scheduled for June 16, 2026, to be held virtually, with voting on five key proposals including director elections, executive compensation, auditor ratification, and an equity plan amendment.
Only stockholders of record as of April 22, 2026, are eligible to vote, with multiple voting methods available including online, phone, mail, and during the meeting.
The board recommends voting for all proposals, including annual say-on-pay votes and the equity plan amendment.
Voting matters and shareholder proposals
Election of three Class III directors for terms expiring at the 2029 annual meeting.
Advisory vote to approve named executive officer compensation (say-on-pay).
Advisory vote on the frequency of say-on-pay votes, with the board recommending every one year.
Ratification of Ernst & Young LLP as independent auditor for fiscal year 2026.
Approval of an amendment to the 2014 Equity Incentive Award Plan to increase the share reserve by 9,000,000 shares.
Board of directors and corporate governance
The board consists of eight members, with all but the CEO considered independent.
The board is classified into three staggered classes, promoting continuity and protection against hostile takeovers.
Committees (audit, compensation, nominating/governance) are fully independent and conduct regular self-evaluations.
The chairperson is independent and separate from the CEO role.
Directors had a 95% average attendance rate in 2025.
Latest events from Ardelyx
- IBSRELA targets $1B+ sales by 2029, with pipeline and cash flow fueling future growth.ARDX
Leerink Global Healthcare Conference 20265 May 2026 - Q1 2026 revenue up 38% to $93.4M, IBSRELA up 58%, net loss narrows, guidance reaffirmed.ARDX
Q1 20264 May 2026 - IBSRELA revenue jumped 73% in 2025, fueling 22% total growth and a strong 2026 outlook.ARDX
Q4 202510 Apr 2026 - Revenue and commercial momentum accelerate as innovative therapies expand and pipeline development advances.ARDX
43rd Annual J.P. Morgan Healthcare Conference 202513 Feb 2026 - TDAPA application for XPHOZAH was declined to protect patient access amid CMS policy changes.ARDX
Business Update3 Feb 2026 - Q2 revenue soared 228% to $73.2M, but XPHOZAH faces 2025 Medicare reimbursement risk.ARDX
Q2 20242 Feb 2026 - Strong product launches and sales force expansion drive growth amid evolving regulatory landscape.ARDX
Jefferies Global Healthcare Conference1 Feb 2026 - IBSRELA and XPHOZAH drive growth amid reimbursement shifts, with global expansion and pipeline focus.ARDX
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Q3 revenue surged 74% year-over-year, led by strong IBSRELA and XPHOZAH sales growth.ARDX
Q3 202417 Jan 2026